Skip navigation
  •  Home
  • UDC 
    • Getting started
    • RUC Policies
    • FAQ
    • FAQ on Copyright
    • More information at INFOguias UDC
  • Browse 
    • Communities
    • Browse by:
    • Issue Date
    • Author
    • Title
    • Subject
  • Help
    • español
    • Gallegan
    • English
  • Login
  •  English 
    • Español
    • Galego
    • English
  
View Item 
  •   DSpace Home
  • 1. Investigación
  • Instituto de Investigación Biomédica da Coruña (INIBIC)
  • Viroloxía clínica
  • INIBIC-VC - Artigos
  • View Item
  •   DSpace Home
  • 1. Investigación
  • Instituto de Investigación Biomédica da Coruña (INIBIC)
  • Viroloxía clínica
  • INIBIC-VC - Artigos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis

Thumbnail
View/Open
Casado_liver.pdf (438.6Kb)
Use this link to cite
http://hdl.handle.net/2183/18398
Collections
  • INIBIC-VC - Artigos [37]
Metadata
Show full item record
Title
Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis
Author(s)
Casado, José Luis
Mena, Álvaro
Bañón, S
Castro-Iglesias, Ángeles
Quereda, C
Moreno, A
Pedreira, José D.
Moreno, S
Date
2015-06-30
Citation
Casado JL, Mena A, Bañón S, et al. Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis. HIV Med. 2016;17(1):62-67
Abstract
[Abstract] Objectives. The aim of the study was to establish the risk of liver toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving etravirine, according to the degree of liver fibrosis. Methods. A prospective cohort study of 211 HIV-infected patients initiating an etravirine-containing regimen was carried out. HCV coinfection was defined as a positive HCV RNA test, and baseline liver fibrosis was assessed by transient elastography. Hepatotoxicity was defined as clinical symptoms, or an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value > 5-fold higher than the upper limit of normal if baseline values were normal, or 3.5-fold higher if values were altered at baseline. Results. Overall, 145 patients (69%) were HCV coinfected, with a lower nadir (165 versus 220 cells/μL, respectively; p = 0.03) and baseline (374 versus 498 cells/μL, respectively; p = 0.04) CD4 count than monoinfected patients. Etravirine was mainly used with two nucleoside reverse transcriptase inhibitors (129; 61%) or with a boosted protease inhibitor (PI) (28%), with no significant differences according to HCV serostatus. Transient elastography in 117 patients (81%) showed a median (range) stiffness value of 8.25 (3.5–69) kPa, with fibrosis stage 1 in 43 patients (37%) and fibrosis stage 4 in 28 patients (24%). During an accumulated follow-up time of 449.3 patient-years (median 548 days), only one patient with advanced fibrosis (50.8 kPa) had grade 3–4 liver toxicity (0.7%). Transaminases changed slightly, with no significant differences compared with baseline fibrosis, and nine and six patients had grade 1 and 2 transaminase increases, respectively. Also, HCV coinfection was not associated with a higher risk of discontinuation (25% discontinued versus 21% of monoinfected patients; p = 0.39, log-rank test) or virological failure (8% versus 12%, respectively; p = 0.4). Conclusions. Our data suggest that etravirine is a safe option for HIV/HCV-coinfected patients, including those with significant liver fibrosis.
Keywords
Etravirine
Hepatotoxicity
Liver fibrosis
Nonnucleoside reverse transcriptase inhibitor
Transient elastography
 
Description
Short communication
Editor version
http://dx.doi.org/10.1111/hiv.12274
Rights
This is the peer reviewed version of the article which has been published in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving
ISSN
1464-2662
1468-1293
 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

View Usage Statistics
Sherpa
OpenArchives
OAIster
Scholar Google
UNIVERSIDADE DA CORUÑA. Servizo de Biblioteca.    DSpace Software Copyright © 2002-2013 Duraspace - Send Feedback